The Role of Targeted Therapy in Craniopharyngioma Management
6th March, 2026, 16:00 - 17:00
Town & Country Ballroom AB
Neurosurgeons, oncologists, radiation oncologists, endocrinologists, and researchers involved in the treatment of skull base and pituitary tumors. This session will explore emerging evidence and clinical applications of BRAF inhibition in the treatment of papillary craniopharyngiomas, highlighting therapeutic strategies, outcomes, and multidisciplinary considerations.
Objectives
At the conclusion of this session, attendees will be able to:
- Evaluate patients with various subtypes of craniopharyngiomas and determine the best multidisciplinary approach for the management of their tumor.
Current Schedule
As a faculty member of this session, you can click on names to email the speaker. Phone numbers are below names
| Speaker | Title | Role | Times |
|---|---|---|---|
| Emmanuel Jouanneau |
- | ||
| Naveed Wagle |
- | ||
| Pamela Jones 6177249117 |
Moderator | - | |
| Christina Jackson 215-662-3487 |
Moderator | - | |
| Priscilla Brastianos 6177241074 |
BRAF/MEK Inhibition for Papillary Craniopharyngiomas | Speaker | 4:00 pm - 4:15 pm |
| Daniel Prevedello 614-293-7190 |
Role of Surgery in the Era of Targeted Therapy for Papillary Craniopharyngioma | Speaker | 4:15 pm - 4:30 pm |
| Christina Jackson 215-662-3487 |
Case Presentation & Discussion: Management of Papillary Craniopharyngioma | Speaker | 4:30 pm - 4:45 pm |
| Viviane Tabar (212) 639-3006 |
Case Presentation & Discussion: Management of Papillary Craniopharyngioma | Speaker | 4:45 pm - 5:00 pm |